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Abstract: In the last few years, oral second-generation antipsychotics have demonstrated 
mood-stabilizing properties and are now widely used in the treatment of bipolar disorder. Unfor-
tunately, treatment of this chronic and complex illness is hampered with poor adherence on the 
part of patients. Long-acting injectable formulations of second-generation antipsychotics could 
combine the effect of oral second-generation antipsychotics in patients with bipolar disorder 
and the benefits of depot formulation with the assurance of steady medication delivery and 
thereby improve adherence. In this context, the efficacy and tolerance of risperidone long-acting 
injection (RLAI) for maintenance treatment in patients with bipolar disorder is assessed. The 
relevant studies found RLAI to be effective in preventive treatment of manic but not depres-
sive recurrences in bipolar patients, with good tolerance. RLAI appeared to be particularly 
suitable for patients with known poor adherence to treatment or severe bipolar disorder (such 
as patients who relapse frequently). Lastly, if RLAI, unlike the first-generation antipsychotics, 
does not induce depressive symptoms, the different studies do not enable us to consider its use 
in monotherapy in the preventive treatment of patients with depressive polarity. Long-acting 
second-generation antipsychotics in bipolar patients are therefore associated with long-term 
benefits, but their use in clinical practice needs to be improved.
Keywords: bipolar disorder, depot antipsychotics, long-acting risperidone injection,   maintenance 
treatment, compliance
Introduction
Bipolar disorder is a chronic disease with a profound social and professional impact, 
and is particularly disabling, with a high suicide risk.1–3 Its periodic course and clinical 
heterogeneity require a complex psychosocial and pharmacologic approach, as well 
as control of compliance.
Treatment nonadherence or partial adherence is common in bipolar disorder. 
A review has reported nonadherence rates ranging from 20% to 66% across studies, 
with a median rate of 41%.4 Nonadherence is the most important predictor of relapse 
and poor prognosis. Patients with bipolar disorder who fail to adhere to pharmaco-
logic treatment have significantly higher rates of hospitalization than fully adherent 
patients.5 Considering that long-acting injectable antipsychotics improve adherence in 
schizophrenic patients,6 bipolar patients experiencing difficulties in maintaining good 
compliance may benefit from such long-acting treatment.
However, the potential long-term side effects with the first-generation depot antip-
sychotics, such as the development of depressive symptoms, have been reported to be a 
problem.7 Some second-generation antipsychotic depots are available, with risperidone, Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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paliperidone, and olanzapine being marketed, and could be 
more beneficial than the first-generation antipsychotics in 
bipolar disorder maintenance treatment.
This review presents current data on the role of long-
acting second-generation antipsychotics, focusing on 
depot risperidone for maintenance treatment in patients 
with bipolar disorder. First, the efficacy of oral risperidone 
in bipolar disorder is reviewed, as well as the benefits 
of use of RLAI compared with the oral formulations. 
Second, the studies of RLAI in the treatment of bipolar 
patients are reviewed. In addition, the profiles of bipolar 
patients who could benefit more specifically from RLAI 
are discussed.
Oral risperidone in bipolar disorder
Second-generation antipsychotics and 
bipolar disorder
In recent times, second-generation antipsychotics have dem-
onstrated mood-stabilizing properties in patients with bipolar 
disorder. Evidence for the efficacy of second-generation 
antipsychotics is mainly focussed on the acute treatment of 
bipolar disorder. In acute mania, studies have demonstrated 
the efficacy of second-generation antipsychotics as mono-
therapy as well as in combination with mood stabilizers 
(lithium or valproate). Few studies of second-generation 
antipsychotic monotherapy have been conducted in   bipolar 
depression.8 Olanzapine was associated with a modest 
  antidepressant effect9 and quetiapine showed efficacy in 
bipolar depression.10
In this context, some psychiatrists have continued second-
generation antipsychotic medication after remission of an 
acute mood episode, and therefore have suggested evidence 
of their efficacy as maintenance therapy. Currently, olan-
zapine, aripiprazole, and quetiapine monotherapy combined 
with lithium or valproate have received US Food and Drug 
Administration (FDA) approval for maintenance treatment 
in bipolar patients.8,11,12
Mood-stabilizing properties of oral 
risperidone
Data from randomized, controlled trials support the efficacy 
of risperidone monotherapy for the treatment of acute mania. 
Risperidone monotherapy was more effective than placebo 
and as effective as lithium or haloperidol in patients with acute 
mania.13–17 Since 2003, the FDA has approved the use of oral 
risperidone for the treatment of acute mania. The combination 
of lithium or valproate with risperidone has demonstrated supe-
rior efficacy compared with lithium or valproate alone.18,19
There is no robust evidence demonstrating the effi-
cacy of risperidone monotherapy in bipolar depression. 
One study compared the effect of risperidone in combina-
tion with   paroxetine, risperidone alone, and paroxetine 
alone, in patients with bipolar depression.20 The results 
showed no   significant difference in improvement in depres-
sive   symptoms between the three groups. However, this 
study was small (n = 30) and the dose of paroxetine in the 
combination group was lower than that used in the mono-
therapy group.
Another randomized study, STEP-BD (Systematic Treat-
ment Enhancement Program for Bipolar Disorder), assessed 
the effectiveness and safety of antidepressant with risperidone, 
lamotrigine, and inositol augmentation in treatment-resistant 
bipolar depression.21 The recovery rate was lower with risperi-
done (4.6%), whereas the recovery rates with lamotrigine and 
inositol were 23.8% and 17.4%, respectively.
The recent guidelines for bipolar disorder proposed 
risperidone only in combination with antidepressants for 
bipolar depression to reduce the risk of switch to mania.22–24 
Risperidone can be considered only as an antimanic 
agent.
The long-term efficacy of oral risperidone has mainly been 
assessed in preventing manic relapse. Initially, several studies 
examined the efficacy and safety of risperidone added on to mood 
stabilizers in the acute and continuation treatment of mania over 
a six-month period.25–28 The results indicated that the combination 
of risperidone with mood stabilizers was effective for acute and 
continuation treatment of mania. Furthermore, risperidone as 
add-on therapy did not induce depressive symptoms.
More recent studies have demonstrated the effectiveness, 
efficacy, and safety of oral risperidone monotherapy for acute 
and continuation treatment of mania.17,29 Risperidone did not 
induce depressive symptoms as part of combination therapy. A 
study of patients with bipolar II disorder has assessed the effec-
tiveness and tolerability of oral risperidone monotherapy and 
in combination with mood stabilizers for acute and continua-
tion treatment of hypomania. At the six-month follow-up, the 
results indicated that risperidone alone or in combination was 
effective. However, risperidone appeared to be more protective 
against hypomania than against   depressive recurrences.26
Risperidone long-acting injection: 
pharmacology, pharmacokinetics 
and benefits on treatment 
adherence
Risperidone is the first second-generation antipsychotic 
for which a long-acting form has been marketed. With the Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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difference of the delayed forms of first-generation antipsy-
chotics, RLAI was developed in the form of microspheres 
containing the active ingredient, with progressive release 
by hydration. The product half-life in this long-acting 
form is assessed at three to six days, with elimination time 
after the first   injection up to eight weeks. Delivery is done 
every 15 days by intramuscular injection, most often in the 
gluteus maximus muscle. Pharmacokinetic studies have 
demonstrated the existence of progressive slow release 
after the first injection, with a period of three weeks before 
obtaining the correct plasma level. The optimal plasma level 
is then obtained within four to six weeks, before progres-
sively decreasing in two weeks.30 Continuing use of oral 
risperidone is therefore recommended for three weeks after 
the first injection.
The pharmacokinetic parameters of long-acting formu-
lations have several advantages compared with oral forms. 
Firstly, the bioavailability is less random by avoiding gas-
trointestinal absorption and the effect of first-pass hepatic 
metabolism, obtaining greater concentrations at the level 
of the central nervous system.31 The doses administered by 
long-acting injections are therefore markedly lower than 
those used orally for the same effect and possibly improve 
tolerance to treatment.32
The ideal stability of the plasma level of the product 
compared with the oral form is also an important element. 
The use of long-acting risperidone ensures improved stability 
in product time and of its active metabolite (risperidone + 
9-hydroxyrisperidone).33 The latter feature improves effi-
cacy, by avoiding variations in plasma levels outside of the 
therapeutic zone.
Tolerance of long-acting risperidone has been widely 
studied.32,34,35 There does not seem to be a major difference 
in terms of neurologic (extrapyramidal) effects, endocrine 
(hyperprolactinemia) tolerance, and weight gain between 
the oral and long-acting forms. The adverse drug reac-
tions linked to injection (pain, inflammation) seem less 
frequent with long-acting risperidone compared with 
first-generation antispychotics.34 It is also advisable to 
highlight the absence of overdose risk and administration 
being controlled, especially in the case of a suicidal medi-
cal history.32
Long-acting injectable formulations of second-gen-
eration antipsychotics could combine the effect of oral 
second-generation antipsychotics in patients with bipolar 
disorder and the benefits of depot formulation, with the 
assurance of steady medication delivery and improved 
adherence.
Studies of long-acting risperidone 
injection in bipolar disorder
Switching from an oral antipsychotic
As monotherapy
An open-label trial conducted during a 12-month follow-up 
period, studied the switch to depot risperidone in 10 patients 
in stable remission previously treated with low-dose oral 
second-generation antipsychotic monotherapy.36 The results 
found no statistically or clinically significant change between 
the baseline and endpoint scores on the Young Mania Rat-
ing Scale (YMRS), Hamilton Rating Scale for Depression 
(HAM-D), and Brief Psychiatric Rating Scale (BPRS). The 
Clinical Global Improvement Scale (CGI-S) significantly 
decreased. Evaluation of patients’ and caregivers’ satisfaction 
using a 10-point visual analog scale indicated a high level of 
satisfaction at the endpoint. Concerning safety assessment, 
there was a significant improvement on the Extrapyramidal 
Symptom Rating Scale and a stable body weight after the 
switch from the oral antipsychotic to RLAI (Table 1).
A recent double-blind, 24-month randomized trial has 
assessed the usefulness of RLAI in monotherapy versus 
placebo to prevent mood episodes in patients with bipolar 
I disorder.37 Inclusion criteria were the existence of a cur-
rent or recent acute manic or mixed episode (with YMRS 
score $20), or the need for euthymic patients (CGI-S 
score #3) to change treatment for safety reasons. Patients 
with more than four mood episodes per year during the last 
two years before the study were excluded. After an open-
label phase, patients who remained stable were randomized 
in two groups, ie, a placebo group and an RLAI continua-
tion group. The results showed a significantly longer time 
to recurrence in the RLAI group (P , 0.001). Recurrence 
was noted in 45 patients (29%) in the RLAI group versus 
78 patients (52%) in the placebo group. Concerning the type 
of mood episode, time to recurrence was significantly longer 
for elevated-mood episodes in the RLAI group (P , 0.001), 
while there was no significant difference for depressive epi-
sodes between the two groups (P = 0.805). Weight gain was 
more important in the RLAI group than in the placebo group. 
The incidence of extrapyramidal symptoms (EPS) was low, 
and serum prolactin concentrations increased from baseline 
during open-label RLAI stabilization and decreased from the 
double-blind baseline in both placebo and RLAI groups.
in combination with other  
mood stabilizers
In a retrospective observational study,38 12 manic or hypo-
manic patients, with a medical history of poor therapeutic Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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compliance, were assessed for six months after the switch 
to RLAI in combination with previous mood stabilizers. 
The results found early and long-lasting improvement 
on the Bech-Rafaelsen Mania Rating Scale (BRMAS) and 
of the CGI-S after treatment with RLAI. No significant modi-
fication of the 24-item HAM-D was observed, and no thymic 
episodes occurred after treatment with depot risperidone. The 
adverse drug reactions listed with RLAI were limited, with 
no EPS-related events documented.
Benabarre et al monitored 14 bipolar and eight schizo-
affective patients over a period of 40 weeks.39 All patients 
presented with low therapeutic compliance caused by a high 
level of relapses. The oral antipsychotic treatments initially 
prescribed were replaced by RLAI and other current mood 
stabilizers were maintained. Under long-acting risperidone 
treatment, the authors observed significant improvements of 
YMRS and CGI-S scores (P , 0.001).
Another observational study, including 29 patients with 
an initial diagnosis of manic or mixed state, monitored 
over two years, assessed the replacement of an oral antip-
sychotic   treatment by RLAI in combination with one or 
several other treatments (mood stabilizer, antipsychotic, 
antidepressant).40 The main objective was to compare the 
number of   hospitalizations related to thymic relapses before 
and after the introduction of RLAI in patients identified as 
noncompliant or barely compliant. The number of hospi-
talizations turned out to be significantly lower during the 
period of RLAI (P , 0.006). The study demonstrated a 
significant reduction in the number of hospitalizations for 
manic or mixed decompensation under RLAI (P , 0.007). 
By contrast, no significant difference was demonstrated 
regarding hospitalizations for depressive episodes (P = 
0.73). An increase in time to relapse was also observed (P 
, 0.001), along with a reduction in the average duration of 
hospitalizations (P , 0.001), after the patients were treated 
with RLAI.
An open randomized study compared RLAI with an 
oral antipsychotic in stable patients with Type I or II bipolar 
disorder.41 Once stabilized by the combination of a mood 
stabilizer and oral antipsychotic, with or without an anti-
depressant, 49 patients were randomized in two groups 
and monitored for a period of six months. In the first group 
(n = 23) the oral antipsychotic was replaced by RLAI; the 
other 26 patients continued their previous oral antipsychotic 
treatment. Efficacy assessments (CGI-S, YMRS, MADRS, 
and Hamilton Anxiety Rating Scale), as well as neurologic 
and biologic tolerance assessments, did not demonstrate a 
significant difference between the two groups.
Adjunctive use with mood stabilizers
An observational study assessed adjunctive use of 
RLAI over a period of two years in 10 bipolar patients 
with predominantly depressive polarity.42 RLAI was 
introduced either because of poor compliance with oral 
treatment or because of poor tolerance or lack of efficacy. 
Eight patients received one or more mood stabilizers in 
combination, three received another antipsychotic, and 
two an antidepressant. The addition of RLAI enabled 
improvement of YMRS scores, as well as a 50% reduction 
in the average number of coprescribed treatments. The 
authors found a minimum increase in MADRS between 
the start and end of the study, with occurrence of a single 
depressive decompensation with a favorable outcome 
under psychotherapy. One manic episode, one hypo-
manic episode, and two mixed episodes were described. 
An improvement in psychosocial functioning was also 
noted, with resumption of professional activity in five 
patients. The treatment was well tolerated in all patients. 
EPS were absent in seven patients and reduced in three 
patients, when compared with their prior medication 
therapy. The average weight gain of 2 kg over two years 
was considered moderate.
A randomized, double-blind study monitored a group 
of 240 patients with bipolar I disorder over a duration of 
68 weeks, following thymic decompensation.43 The main 
characteristic of patients in this study was a high number of 
thymic episodes (at least four) over the previous 12 months. 
After 16 weeks receiving RLAI combined with one or more 
treatments (antidepressants, mood stabilizers, anxiolytics), 
124 who patients stabilized for at least four weeks were 
randomized into two groups. Sixty-five patients therefore 
received RLAI as adjunctive therapy, and 59 received pla-
cebo. The addition of RLAI increased the time to relapse 
(P = 0.010) and decreased the number of relapses (P = 0.011) 
compared with the placebo group, regardless to the type 
of thymic episode. EPS and weight gain (P = 0.002) were 
found to have a significantly greater incidence in the RLAI 
group. Potential prolactin-related adverse effects (erectile 
dysfunction, decreased libido, amenorrhea) and mean 
changes in laboratory values for glucose, cholesterol, and 
triglycerides were similar between the adjunctive RLAI and 
placebo groups.
impact on therapeutic compliance
Some authors describe fewer relapses when moving from an 
oral form of antipsychotic to RLAI,36,40 probably because the 
latter formulation enables better compliance.31Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Several studies have tried to define the relevance of RLAI 
in the specific group of noncompliant or barely compliant 
patients.38–40 In specific category of patients, the efficacy results 
were in favor of the long-acting formulation. Moreover, these 
studies highlight good tolerance of the product in the long-acting 
form, suggesting better adherence to treatment. Vieta et al40 have 
demonstrated a significant   improvement in overall compliance, 
including with oral treatments, and a decrease in the rate of poor 
compliance from 86% to 27.5% with RLAI (P , 0.0001).
Discussion
Profile of eligible patients
The bulk of the data suggests that monotherapy RLAI is effec-
tive in the preventive treatment of manic but not depressive 
recurrences in bipolar patients. The profile of patients who 
can benefit from the use of RLAI seems to be influenced by 
both patient- and illness-related factors.
Patient-related factors
Patient compliance after prescription of prophylactic treat-
ment is an individual factor which plays a central role in the 
prevention of thymic recurrences. In practice, we can describe 
a subgroup of bipolar patients with a low level of treatment 
compliance. This subgroup shows an improvement in compli-
ance after introducing RLAI (as monotherapy or as part of 
a combination). Studies including patients with a history of 
poor adherence to treatment have found that RLAI improved 
therapeutic efficacy in the long term, with an improvement in 
the YMRS and CGI-S scores, increased time before relapse, 
and a reduction in the number of hospitalizations associated 
with the same (or even better) level of treatment tolerance.
The subpopulation of nonadherent bipolar patients is 
associated with particular sociodemographic and clinical 
characteristics, such as young age, male gender, mainly single 
or separated marital status, low educational levels, psychiatric 
comorbidity, drug abuse, and personality disorders.40,44 These 
characteristics could be an argument for the priority use of 
RLAI in long-term treatment. However, full compliance 
with treatment is difficult to obtain in the majority of chronic 
illnesses.45 The use of RLAI in maintenance treatment for 
all bipolar patients is therefore relevant. Nevertheless, the 
long-term gain obtained after the introduction of RLAI will 
be greater in patients with poor adherence to treatment.
Bipolar disorder-related factors
Dominant thymic polarity
The studies presented in this review indicate that RLAI is 
effective in preventing relapse in mania during long-term 
treatment. More specifically, the studies indicate efficacy as 
monotherapy and in combination with mood stabilizers in 
preventing relapse of manic episodes. Efficacy in prevent-
ing relapse of depressive episodes was also shown but only 
in treatments combining RLAI with other mood stabilizers. 
No data were available to assess efficacy as monotherapy in 
preventing relapse of depression.
The RLAI monotherapy studies are the most commonly 
provided in monitoring manic or mixed episodes, where 
the latest episode is often correlated to the thymic polarity 
of the relapse.46 These patients were more at risk of manic 
recurrences which could explain a lower rate of depressive 
relapse than manic relapses. However, compared with first-
generation antipsychotics, monotherapy with RLAI does 
not worsen symptoms of depression in patients presenting 
mania or mixed states.
Since the early 1980s, several studies have assessed the 
efficacy and safety of first-generation depot antipsychotics 
in patients with bipolar disorder. A review of these studies 
showed that these agents decrease the frequency and sever-
ity of manic symptoms during maintenance treatment, but 
also that they may worsen the depressive phase of bipolar 
disorder.7 Some studies reported several suicides as a result 
of worsening depression.47
The first-generation antipsychotics do not show any rel-
evance in the maintenance treatment of bipolar patients in 
contrast with RLAI which, through the absence of induction 
of depressive symptoms, may be considered as a prophylactic 
treatment in monotherapy in patients with manic polarity.
The absence of data in bipolar patients with depressive 
polarity does not seem to allow the long-term use of RLAI 
in monotherapy, but it can be used in combination with other 
mood stabilizers.
Severity of bipolar disorder
To our knowledge, there is no consensual definition of 
severe bipolar disorder. The severity of the disorder can be 
defined using a dimensional or longitudinal approach, as 
well as categoric criteria. The current classifications tend to 
assess severity of illness on a dimensional basis according 
to intensity of symptoms (number of symptoms present), 
their impact, or presence of psychotic symptoms. Occur-
rence of hyperthymic episodes, using precise categories, 
such as mixed episode, defines the severity of bipolar dis-
order. From a longitudinal viewpoint, chronicity, number of 
recurrences, adherence to treatment, and impact on quality 
of life can be taken into account to define the severity of 
bipolar disorder.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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The studies shown in this review most often assessed 
severity using dimensional scales (eg, YMRS, MADRS, and 
CGI-S) to assess changes during treatment. Some authors 
have also assessed the use of RLAI in patient categories asso-
ciated with severe bipolar disorder, ie, patients with frequent 
recurrences (at least four times over the last 12 months),43 
ie, patients who presented poor adherence to treatment.38–40 
The use of RLAI combined with other mood stabilizers in 
the treatment of severe bipolar disorder appeared to be more 
effective than combinations of oral medication, and remain 
associated with maintenance of good tolerance.38–40,43
Use of oral second-generation antipsychotics in bipo-
lar disorder is recommended during thymic episodes with 
psychotic symptoms. It will be noticed that no study has 
attempted to demonstrate the efficacy of RLAI in patients 
presenting during relapses of thymic episodes associated 
with psychotic symptoms by taking into account the presence 
of these symptoms as well. The relevance of RLAI for this 
subgroup of patients still needs to be demonstrated.
Clinical limitations
The studies described in this review demonstrate a safety 
profile for RLAI consistent with that previously observed 
in short- and long-term studies, with no emergence of new 
safety issues in patients with schizophrenia.34,48–50 When 
compared with oral formulations, the long-acting formula-
tion seems to cause fewer neurologic adverse effects, espe-
cially EPS, while prolactin-related adverse events occur at 
a similar rate.
Among the second-generation antipsychotics, risperidone 
appears to be the molecule with the higher risk for neurologic 
and endocrine adverse events.51 However, such reactions 
remain less frequent in comparison with those associated with 
the first-generation antipsychotics.52 When using risperidone, 
weight gain and metabolism disorders occur as frequently as 
for most second-generation antipsychotics.51
At present, there are no specific studies dealing with 
the tolerance of RLAI in comparison with other mood 
stabilizers, such as lithium and the anticonvulsants. Toler-
ance profiles of these last medications are associated with 
another range of adverse effects, such as thyroid abnormali-
ties and renal or hepatic reactions, which differ from those 
described with RLAI use. Consequently, the benefit:risk 
ratio for RLAI, as for other medications, should be evalu-
ated individually, taking into account personal and familial 
antecedents and results of clinical examination or biologic 
assessments. RLAI may not be suitable for all patients with 
bipolar disorder.
Methodological limitations
Most of the studies included in this review suffered from 
several methodologic limitations. Only two large studies 
were randomized controlled trials,37,43 and most were small, 
open-label trials or retrospective reviews. Some studies also 
included a mixture of bipolar and schizoaffective patients 
or used combination medications, and none compared 
RLAI with oral risperidone or oral second-generation 
  antipsychotics. Given the limited evidence, other long-term 
studies employing randomized, controlled and blinded 
designs, along with dominant thymic polarity patients 
  (especially depressive polarity) are needed.
Positioning of RLAi in guidelines for 
bipolar disorder management
Most guidelines recommended use of long-term medication 
according to the dominant thymic polarity.22,23 First-line 
medications are lithium, valproate, aripiprazole, and olan-
zapine for predominantly manic patients and quetiapine and 
lamotrigine for predominantly depressive patients.
Because of the low level of evidence for RLAI, it is 
mentioned in guidelines as second- or third-line prophylac-
tic treatment for bipolar disorder (except for the CANMAT 
guidelines for bipolar disorder24 which recommend RLAI as 
a first-line therapy). However, few guidelines have considered 
the usefulness of RLAI versus other maintenance treatment 
options in poorly compliant bipolar patients at high risk 
for manic relapse or as adjunctive medication with another 
mood stabilizer.22,23
Conclusion
If use of long-acting first-generation antipsychotics is to be 
avoided in the treatment of bipolar patients due to increased 
risk of promoting appearance of depressive symptoms, and in 
particular increasing the risk of suicide, long-acting second-
generation antipsychotics, such as RLAI, may be considered 
for maintenance treatment of bipolar patients. RLAI appears 
to be particularly suitable for patients presenting with poor 
adherence or with severe bipolar disorder. However, the pres-
ent data necessitate taking into account the individual safety 
profile and the thymic polarity of the bipolar patient. RLAI 
can be used as monotherapy in patients with manic polarity, 
but RLAI should always be considered for use in combina-
tion with at least one other mood stabilizer in patients with 
depressive polarity.
In clinical practice, the prescription of RLAI in psychotic 
patients is still not very high by psychiatrists (,10%).53 The 
negative attitude of patients to RLAI seems to be correlated Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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with a low level of information from psychiatrists about 
the medication,54 because patients who receive treatment 
with RLAI report an increase in satisfaction with their 
treatment.55
The clinical use of long-acting second-generation antip-
sychotics in bipolar patients requires that better information 
on the formulation be relayed from psychiatrists to their 
patients.
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